StreetAlpha.app
Home › Stocks › AVIR

Atea Pharmaceuticals, Inc. (AVIR)

$3.96
▲ +0.76%
LAST CLOSE · NOV 20

Atea Pharmaceuticals develops oral antiviral medicines for hepatitis C and hepatitis E, and none are yet approved. It last closed at $3.96 on Nov 20, up 0.76% on the day. The next earnings report for AVIR is expected around Thu, Mar 4, 2027, after the close. For the quarter ended Sep 2026, AVIR reported EPS of -$0.40. Over its last 8 reports the stock moved an average of 6.6% the session after earnings. Over the last 12 months AVIR insiders bought $0 of stock on the open market and sold $320K, according to SEC Form 4 filings.

AI Auto Pilots
Is AVIR in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold AVIR.

Key Stats

Last 12 months
Results
Net income
−$155.4M
EPS (diluted)
−$1.95
Valuation
Market cap
$318.0M
80.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$97.9M
At Sep 30
Shareholder equity
$175.7M
Shares outstanding
80.3M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $121.2M$121.2MFY2021FY2022: −$115.9M−$115.9MFY2022FY2023: −$136.0M−$136.0MFY2023FY2024: −$168.4M−$168.4MFY2024FY2025: −$158.3M−$158.3MFY2025

From AVIR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Mar 4
Estimated date · After the close
Reported EPS
-$0.40
Quarter ended Sep 2026
Year ago EPS
-$0.53
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.40Dec '24Mar 2025: -$0.40Mar '25Jun 2025: -$0.44Jun '25Sep 2025: -$0.53Sep '25Dec 2025: -$0.57Dec '25Mar 2026: -$0.57Mar '26Jun 2026: -$0.41Jun '26Sep 2026: -$0.40Sep '26Latest -$0.40
Revenue by quarter
Not enough quarters on file yet.
How AVIR moved after its last 8 reports
Average move the session after a report ±6.6%
Nov 9, 2026After the close−4.8%
Aug 12, 2026After the close+0.2%
May 12, 2026After the close−16.9%
Mar 5, 2026After the close+11.1%
Jan 8, 2026Time not announced+3.7%
Nov 12, 2025After the close−12.6%
Aug 7, 2025After the close−2.3%
Apr 17, 2025Time not announced−1.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on AVIRStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on AVIR
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on AVIR

Technical Analysis

AVIR · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 6% below its 20 day and 17% below its 50 day average. It is 25% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 37), near oversold. The nearest support is the Pivot at $3.95, and the nearest resistance the Pivot R1 at $4.10.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 6.2%/day
Key levels
$6.4552 week high+62.9%
$4.95200 day average+25.0%
$4.86100 day average+22.7%
$4.6550 day average+17.4%
$4.38Swing high (Nov 16)+10.6%
$4.1820 day average+5.6%
$4.10Pivot R1+3.5%
$3.96Last close
$3.95Pivot−0.3%
$3.94Swing low (Nov 2)−0.5%
$3.81Pivot S1−3.8%
$2.9252 week low−26.3%
Indicators
RSI (14)37.46Weak, oversold below 30Neutral
MACD-0.17Below its signal lineBearish
Stochastic19.0Near the bottom of its rangeOversold
ADX (14)28.3Trending down
Williams %R-77.0Oversold below −80, overbought above −20Neutral
CCI (20)-150.1Oversold below −100, overbought above 100Oversold
Rate of change−8.1%Change over 10 sessionsBearish
ATR (14)$0.24Typical daily range, 6.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for AVIR

What happened before

See how AVIR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow AVIR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How AVIR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for AVIRHow many large options trades hit AVIR, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

AVIR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲61 buying vs 46 selling
  • ●Held by funds -0.3 pts
  • ●Funds holding +1
  • ▼Superinvestors: 0 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding127126+0.8%
In funds' top 10110.0%
Held by funds73.7%74.0%−0.3 pts
New / increased14 / 4719 / 45−4.7%
Reduced / sold out34 / 1238 / 20−20.7%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AVIR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AVIR Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$320K3 sales · 2 insiders
2026-11 sold $320KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 19Bruce PolskyDirectorSale8,750$4.03$35K
Nov 19Bruno LucidiDirectorSale29,360$3.96$116K
Nov 18Bruce PolskyDirectorSale41,226$4.08$168K
May 18, 2025Polly A. MurphyDirectorBuy6,100$4.17$25K
Dec 10, 2024Franklin M BergerDirectorSale359,606$2.85$1.0M
Every insider buy and sale for AVIR over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See AVIR insider trades →

From SEC Form 4 filings by AVIR's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AVIR is in one of them and how their past AVIR trades turned out.

AVIR in the AI portfolios
Loading…

AVIR News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AVIR in an article yet. Here's the latest on the wider market.

AVIR in the news

About Atea Pharmaceuticals

Atea Pharmaceuticals is a biopharmaceutical company based in Boston, Massachusetts. It is developing oral antiviral medicines for serious viral diseases. Its main candidates are a two drug regimen for hepatitis C, which is still in clinical trials, and a treatment for hepatitis E in patients with weakened immune systems. The company builds these candidates from a proprietary platform of nucleotide compounds.

Headquarters
Boston, MA